Humana Antithrombotic Drug Therapy in Cardiovascular Disease (Contemporary Cardiology)

Written by experts in the field, this book provides a comprehensive overview of the pathophysiology, including the genetics, of arterial and venous thrombosis. It also presents the evidence demonstrating the efficacy of available antithrombotic therapies. Review From the reviews: Despite substantial therapeutic progress, considerable morbidity and mortality remains associated with thrombotic events but rapid expansion of the available armamentarium to combat pathologic thrombosis is nicely summarized in this excellent new book which becomes a valuable guide to improved therapy. The experts from the field, selected by its editors, survey individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors). The treatments discussed are up-to-date methods for management of common cardiovascular thrombotic problems designed for appropriate clinical use. Numerous illustrations, tables and figures throughout the book become particularly helpful for the reader. There are seven major divisions covered by twenty four chapters; most of which are multi-authored and include: Basic Principles, Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease, Antithrombotic Therapy for NSTE ACS, Antithrombotic Therapy for STEMI. Antithrombotic Therapy in Interventional Cardiology, Antithrombotic Therapy in Venous Thromboembolism, and Clinical Considerations. The coagulationist should find this text to be a valuable addition to his/her office reference book shelf. William H Wehrmacher MD FACP FACC Harry L Messmore MD FACP from Comprehensive Therapy - 2010 “The chapter authors of this multiauthored book on antithrombotic drug therapy in cardiovascular disease are national and international thought leaders in their respective fields. … The intended audience includes medical students, allied health professionals, physicians in training, and cardiovascular physicians. … This will be a valuable resource for healthcare providers in the field of cardiovascular disease management. The authors have met their objective of providing a high quality, evidence-based review of this field.” (Timir Paul, Doody’s Review Service, March, 2009) From the Back Cover Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT).